
AlphaTau
Alpha Tau Medical focuses on research, development and commercialization of Alpha DaRT for the treatment of solid cancer tumors.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor investor investor investor | €0.0 | round |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
* | $36.9m | Post IPO Equity | |
Total Funding | 000k |












USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Alpha Tau Medical Ltd. is a pioneering medical technology company specializing in the development of advanced cancer treatments. The company focuses on patients with localized and unresectable tumors, particularly those who have limited alternative treatment options. Alpha Tau operates in the oncology market, targeting tumor types with high unmet needs such as pancreatic adenocarcinoma, glioblastoma, skin cancer, oral cavity cancer, and breast cancer. The core product, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), delivers localized radiation to destroy solid tumors while sparing surrounding healthy tissue. This innovative approach minimizes radioactive exposure and has shown promising results in combination with immunotherapies and other systemic treatments. Alpha Tau generates revenue through clinical trials and partnerships with leading cancer research institutions. The business model is centered on developing and commercializing its proprietary technology to address significant gaps in current cancer treatment options.
Keywords: oncology, cancer treatment, localized radiation, Alpha DaRT, solid tumors, immunotherapy, clinical trials, medical technology, unresectable tumors, advanced therapies.